

# Review on Psoriasis Disease

**Yash Ashokrao Makode, Prof. Rajlaxmi S. Deolekar, Pritesh R. Bele**

New Montfort Institute of Pharmacy, Ashti, Wardha, Maharashtra, India  
yashmakode2002@gmail.com

**Abstract:** *Psoriasis is a rather common inflammatory skin disease that is characterized by the appearance of red scaly plaques and may affect any part of the body. There are certain factors that make psoriasis a challenge for physicians, these include: high prevalence, disability, chronicity, disfigurement, and associated comorbidities. The approach to the management of Psoriatic patients should also take into account the dermatological clinical features. This review would discuss and focus on recent updates in the management of Psoriatic patients and its common related issues as well as the clinical picture of psoriasis in order to understand and inform medical practitioners and develop their knowledge of the etiology of the condition, immune and environmental factors, has led to the development of precision-targeted therapies that alleviate patient morbidity*

**Keywords:** Psoriasis, management of psoriatic patients, treatment, skin disease, therapies.

## REFERENCES

- [1]. Y. Liu, J. G. Krueger and A. M. Bowcock, *Genes Immun.*, 2007, 8, 1–12.
- [2]. H. Valdimarsson, R. H. Thorleifsdottir, S. L. Sigurdardottir, J. E. Gudjonsson and A. Johnston, *Trends Immunol.*, 2009, 30, 494–501.
- [3]. A. M. Bowcock, *Annu. Rev. Genomics Hum. Genet.*, 2005, 6, 93–122.
- [4]. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. *Clin Exp Rheumatol.* 2015;33(5)(suppl 93):S2-S6.
- [5]. Gourraud PA, Le Gall C, Puzenat E, Aubin F, Ortonne JP, Paul CF. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. *J Invest Dermatol.* 2012;132(9):2171-5.
- [6]. Otero ME, van Geel MJ, Hendriks JC, van de Kerkhof PC, Seyger MM, de Jong EM. A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas: Presentation and implications of the Low PASI score. *J Dermatolog Treat.* 2015;26(4):314-7.
- [7]. Muramatsu S, Kubo R, Nishida E, Morita A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. *Mod Rheumatol.* 2017;27(1):137-41.
- [8]. Mihatsch MJ, Wolff K. Consensus conference on cyclosporin A for psoriasis. *Br J Dermatol* 1992; 126(6):621–3.
- [9]. A. Menter, N. J. Korman, C. A. Elmets, S. R. Feldman, J. M. Gelfand, K. B. Gordon, A. Gottlieb, J. Y. Koo, M. Lebwohl, H. W. Lim, A. S. Van Voorhees, K. R. Beutner, R. Bhushan and American Academy of Dermatology, *J. Am. Acad. Dermatol.*, 2009, 60, 643–659.
- [10]. W. H. Boehncke, S. Boehncke, A. M. Tobin and B. Kirby, *Exp. Dermatol.*, 2011, 20, 303–307.
- [11]. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. *Am J Cardiol.* 2011;108(9):1362-70.